Industry
Biotechnology
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Insights
April 15, 2024 | 12:07 pm
Portfolio Pulse from Benzinga Newsdesk
March 07, 2024 | 1:43 pm
Portfolio Pulse from Charles Gross
February 23, 2024 | 1:19 am
Portfolio Pulse from Benzinga Newsdesk
February 22, 2024 | 11:55 pm
Portfolio Pulse from Charles Gross
February 21, 2024 | 10:43 pm
Portfolio Pulse from Benzinga Newsdesk
February 21, 2024 | 10:41 pm
Portfolio Pulse from Benzinga Insights
February 06, 2024 | 1:06 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.